- Home
- TWIN vs TCRX Comparison
TWIN vs TCRX Comparison
Compare TWIN & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- TCRX
- Stock Information
- Founded
- TWIN 1918
- TCRX 2018
- Country
- TWIN United States
- TCRX United States
- Employees
- TWIN N/A
- TCRX N/A
- Industry
- TWIN Industrial Machinery/Components
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- TWIN Industrials
- TCRX Health Care
- Exchange
- TWIN Nasdaq
- TCRX Nasdaq
- Market Cap
- TWIN 97.0M
- TCRX 91.7M
- IPO Year
- TWIN N/A
- TCRX 2021
- Fundamental
- Price
- TWIN $9.01
- TCRX $1.65
- Analyst Decision
- TWIN Strong Buy
- TCRX Strong Buy
- Analyst Count
- TWIN 1
- TCRX 6
- Target Price
- TWIN $12.00
- TCRX $9.50
- AVG Volume (30 Days)
- TWIN 26.6K
- TCRX 282.5K
- Earning Date
- TWIN 08-21-2025
- TCRX 08-19-2025
- Dividend Yield
- TWIN 1.77%
- TCRX N/A
- EPS Growth
- TWIN N/A
- TCRX N/A
- EPS
- TWIN 0.29
- TCRX N/A
- Revenue
- TWIN $328,478,000.00
- TCRX $4,421,000.00
- Revenue This Year
- TWIN $17.34
- TCRX $159.20
- Revenue Next Year
- TWIN $9.01
- TCRX N/A
- P/E Ratio
- TWIN $31.07
- TCRX N/A
- Revenue Growth
- TWIN 11.49
- TCRX N/A
- 52 Week Low
- TWIN $6.16
- TCRX $1.02
- 52 Week High
- TWIN $13.40
- TCRX $6.38
- Technical
- Relative Strength Index (RSI)
- TWIN 54.90
- TCRX 45.05
- Support Level
- TWIN $8.60
- TCRX $1.60
- Resistance Level
- TWIN $9.21
- TCRX $1.87
- Average True Range (ATR)
- TWIN 0.27
- TCRX 0.12
- MACD
- TWIN -0.02
- TCRX -0.03
- Stochastic Oscillator
- TWIN 72.60
- TCRX 12.37
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.